TrialBMC cancer2019

Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.

Zsuzsanna Kahan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.